HPV16-E7 Expression in Squamous Epithelium Creates a Local Immune Suppressive Environment via CCL2- and CCL5- Mediated Recruitment of Mast Cells

English version České info

Worldwide, around 50% of sexually active women are believed to become infected by Human papillomavirus type 16, the major cause of cervical cancer, and 2% will remain infected and therefore at lifetime risk of developing cancer. Why some women remain infected is unknown. Here we used a mouse engineered to express the HPV16 protein (E7) in skin, which drives development of pre-cancer lesions. This protein induces skin thickening, and the thickened skin releases molecules that attract mast cells. We show further that these cells locally suppress the function of the immune effector cells that can reject E7 expressing skin. We believe that targeting mast cells or impairing their attraction to the HPV infected tissue might therefore reduce the risk of cervical cancer for women infected with HPV16 by enabling them to clear their chronic infection.

Vyšlo v časopise: HPV16-E7 Expression in Squamous Epithelium Creates a Local Immune Suppressive Environment via CCL2- and CCL5- Mediated Recruitment of Mast Cells. PLoS Pathog 10(10): e32767. doi:10.1371/journal.ppat.1004466
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004466

Souhrn

Zdroje

1. WoodsRS, O'ReganEM, KennedyS, MartinC, O'LearyJJ, et al. (2014) Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. World J Clin Cases 2: 172–193.

2. FrazerIH, LeggattGR, MattarolloSR (2011) Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 29: 111–138.

3. GalliSJ, TsaiM (2012) IgE and mast cells in allergic disease. Nat Med 18: 693–704.

4. SayedBA, ChristyA, QuirionMR, BrownMA (2008) The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 26: 705–739.

5. KobayashiA, GreenblattRM, AnastosK, MinkoffH, MassadLS, et al. (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64: 6766–6774.

6. BergotAS, KassianosA, FrazerIH, MittalD (2011) New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) 3: 3461–3495.

7. MunozN, BoschFX, de SanjoseS, HerreroR, CastellsagueX, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527.

8. ChoyceA, YongM, NarayanS, MattarolloSR, LiemA, et al. (2013) Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes. PloS one 8: e57798.

9. FiorenzaS, KennaTJ, ComerfordI, McCollS, SteptoeRJ, et al. (2012) A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J Immunol 189: 5622–5631.

10. MattarolloSR, YongM, GosmannC, ChoyceA, ChanD, et al. (2011) NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins. J Immunol 187: 1601–1608.

11. RahimpourA, MattarolloSR, YongM, LeggattGR, SteptoeRJ, et al. (2012) gammadelta T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skin-derived antigen. J Invest Dermatol 132: 1656–1664.

12. MattarolloSR, RahimpourA, ChoyceA, GodfreyDI, LeggattGR, et al. (2010) Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. J Immunol 184: 1242–1250.

13. ChanCY, St JohnAL, AbrahamSN (2013) Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38: 349–359.

14. GalliSJ, GrimbaldestonM, TsaiM (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8: 478–486.

15. GrimbaldestonMA, NakaeS, KalesnikoffJ, TsaiM, GalliSJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8: 1095–1104.

16. Leveson-GowerDB, SegaEI, KalesnikoffJ, FlorekM, PanY, et al. (2013) Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood 122: 3659–3665.

17. CoussensLM, RaymondWW, BergersG, Laig-WebsterM, BehrendtsenO, et al. (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382–1397.

18. BalsitisS, DickF, LeeD, FarrellL, HydeRK, et al. (2005) Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J Virol 79: 11392–11402.

19. KambeN, KambeM, KochanJP, SchwartzLB (2001) Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood 97: 2045–2052.

20. ShamlooA, ManchandiaM, FerreiraM, ManiM, NguyenC, et al. (2013) Complex chemoattractive and chemorepellent Kit signals revealed by direct imaging of murine mast cells in microfluidic gradient chambers. Integr Biol (Camb) 5: 1076–1085.

21. GrimbaldestonMA, ChenCC, PiliponskyAM, TsaiM, TamSY, et al. (2005) Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167: 835–848.

22. NigrovicPA, GrayDH, JonesT, HallgrenJ, KuoFC, et al. (2008) Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol 173: 1693–1701.

23. Schafer B, Piliponsky AM, Oka T, Song CH, Gerard NP, et al. (2013) Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice. J Allergy Clin Immunol 131: 541–548 e541–549.

24. DudeckA, DudeckJ, ScholtenJ, PetzoldA, SurianarayananS, et al. (2011) Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34: 973–984.

25. MaurerM, WedemeyerJ, MetzM, PiliponskyAM, WellerK, et al. (2004) Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432: 512–516.

26. KhazaieK, BlatnerNR, KhanMW, GounariF, GounarisE, et al. (2011) The significant role of mast cells in cancer. Cancer Metastasis Rev 30: 45–60.

27. BoermaM, FiserWP, HoytG, BerryGJ, JosephL, et al. (2007) Influence of mast cells on outcome after heterotopic cardiac transplantation in rats. Transpl Int 20: 256–265.

28. de VriesVC, Pino-LagosK, NowakEC, BennettKA, OlivaC, et al. (2011) Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 35: 550–561.

29. LuLF, LindEF, GondekDC, BennettKA, GleesonMW, et al. (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997–1002.

30. AndreuP, JohanssonM, AffaraNI, PucciF, TanT, et al. (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121–134.

31. TranT, BarlowB, O'RearL, JarvisB, LiZ, et al. (2011) Loss of the alpha2beta1 integrin alters human papilloma virus-induced squamous carcinoma progression in vivo and in vitro. PLoS One 6: e26858.

32. HalovaI, DraberovaL, DraberP (2012) Mast cell chemotaxis - chemoattractants and signaling pathways. Front Immunol 3: 119.

33. HuangB, LeiZ, ZhangGM, LiD, SongC, et al. (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269–1279.

34. OkayamaY, KawakamiT (2006) Development, migration, and survival of mast cells. Immunol Res 34: 97–115.

35. ChenCC, GrimbaldestonMA, TsaiM, WeissmanIL, GalliSJ (2005) Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 102: 11408–11413.

36. CoussensLM, HanahanD, ArbeitJM (1996) Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149: 1899–1917.

37. RuffellB, AffaraNI, CottoneL, JunankarS, JohanssonM, et al. (2013) Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 27: 2086–2098.

38. PiliponskyAM, ChenCC, GrimbaldestonMA, Burns-GuydishSM, HardyJ, et al. (2010) Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. Am J Pathol 176: 926–938.

39. LeeJO, RussoAA, PavletichNP (1998) Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391: 859–865.

40. MattarolloSR, YongM, TanL, FrazerIH, LeggattGR (2010) Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen. J Immunol 184: 5663–5669.

41. DanoffTM, LalleyPA, ChangYS, HeegerPS, NeilsonEG (1994) Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES. J Immunol 152: 1182–1189.

42. Kleine-LowinskiK, RheinwaldJG, FichorovaRN, AndersonDJ, BasileJ, et al. (2003) Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 107: 407–415.

43. CirilliA, SimeoneP, MullerA, BagnatoA, VenutiA (2004) Targeting endothelin receptor type A in human cervical carcinoma cells. J Cardiovasc Pharmacol 44 Suppl 1S72–75.

44. BagnatoA, LoizidouM, PflugBR, CurwenJ, GrowcottJ (2011) Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163: 220–233.

45. HartPH, GrimbaldestonMA, SwiftGJ, JaksicA, NoonanFP, et al. (1998) Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med 187: 2045–2053.

46. de VriesVC, ElguetaR, LeeDM, NoelleRJ (2010) Mast cell protease 6 is required for allograft tolerance. Transplant Proc 42: 2759–2762.

47. GalliSJ, KalesnikoffJ, GrimbaldestonMA, PiliponskyAM, WilliamsCM, et al. (2005) Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23: 749–786.

48. DaltonDK, NoelleRJ (2012) The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 61: 1511–1520.

49. PittoniP, TripodoC, PiconeseS, MauriG, ParenzaM, et al. (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71: 5987–5997.

50. WilkM, LiszkaL, PalenP, GabrielA, LaudanskiP (2010) Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions - are they correlated? Pathol Res Pract 206: 217–222.

51. HodgesK, KennedyL, MengF, AlpiniG, FrancisH (2012) Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Transl Gastrointest Cancer 1: 138–150.

52. TanakaT, IshikawaH (2013) Mast cells and inflammation-associated colorectal carcinogenesis. Semin Immunopathol 35: 245–254.

53. StrouchMJ, CheonEC, SalabatMR, KrantzSB, GounarisE, et al. (2010) Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 16: 2257–2265.

54. GrimbaldestonMA, SimpsonA, Finlay-JonesJJ, HartPH (2003) The effect of ultraviolet radiation exposure on the prevalence of mast cells in human skin. The British journal of dermatology 148: 300–306.

55. KempTJ, HildesheimA, SafaeianM, DaunerJG, PanY, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011–2014.

56. VillaLL, CostaRL, PettaCA, AndradeRP, PaavonenJ, et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466.

57. VinzonSE, Braspenning-WeschI, MullerM, GeisslerEK, NindlI, et al. (2014) Protective Vaccination against Papillomavirus-Induced Skin Tumors under Immunocompetent and Immunosuppressive Conditions: A Preclinical Study Using a Natural Outbred Animal Model. PLoS Pathog 10: e1003924.

58. FrazerIH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4: 46–54.

59. TrimbleCL, FrazerIH (2009) Development of therapeutic HPV vaccines. Lancet Oncol 10: 975–980.

60. O'BrienPM, Saveria CampoM (2002) Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res 88: 103–117.

61. FridlenderZG, BuchlisG, KapoorV, ChengG, SunJ, et al. (2010) CCL2 blockade augments cancer immunotherapy. Cancer Res 70: 109–118.

62. QianBZ, LiJ, ZhangH, KitamuraT, ZhangJ, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222–225.

63. HuangB, LeiZ, ZhaoJ, GongW, LiuJ, et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252: 86–92.

64. Yip KH, Kolesnikoff N, Yu C, Hauschild N, Taing H, et al. (2014) Mechanisms of vitamin D(3) metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol 133: 1356–1364, 1364 e1351–1314.